Clinuvel Pharmaceuticals Limited

CHIA:CUV Stock Report

Market Cap: AU$598.9m

Clinuvel Pharmaceuticals Management

Management criteria checks 2/4

Clinuvel Pharmaceuticals' CEO is Philippe Wolgen, appointed in Nov 2005, has a tenure of 19.17 years. total yearly compensation is A$3.74M, comprised of 47.2% salary and 52.8% bonuses, including company stock and options. directly owns 6.86% of the company’s shares, worth A$41.07M. The average tenure of the management team and the board of directors is 1.1 years and 5.2 years respectively.

Key information

Philippe Wolgen

Chief executive officer

AU$3.7m

Total compensation

CEO salary percentage47.2%
CEO tenure19.2yrs
CEO ownership6.9%
Management average tenure1.1yrs
Board average tenure5.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Philippe Wolgen's remuneration changed compared to Clinuvel Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$4mAU$2m

AU$36m

Mar 31 2024n/an/a

AU$33m

Dec 31 2023n/an/a

AU$30m

Sep 30 2023n/an/a

AU$30m

Jun 30 2023AU$6mAU$2m

AU$31m

Mar 31 2023n/an/a

AU$29m

Dec 31 2022n/an/a

AU$26m

Sep 30 2022n/an/a

AU$24m

Jun 30 2022AU$7mAU$1m

AU$21m

Mar 31 2022n/an/a

AU$22m

Dec 31 2021n/an/a

AU$24m

Sep 30 2021n/an/a

AU$24m

Jun 30 2021AU$5mAU$2m

AU$25m

Mar 31 2021n/an/a

AU$23m

Dec 31 2020n/an/a

AU$21m

Sep 30 2020n/an/a

AU$18m

Jun 30 2020AU$3mAU$2m

AU$15m

Mar 31 2020n/an/a

AU$15m

Dec 31 2019n/an/a

AU$15m

Sep 30 2019n/an/a

AU$16m

Jun 30 2019AU$1mAU$894k

AU$18m

Mar 31 2019n/an/a

AU$17m

Dec 31 2018n/an/a

AU$16m

Sep 30 2018n/an/a

AU$15m

Jun 30 2018AU$2mAU$818k

AU$13m

Compensation vs Market: Philippe's total compensation ($USD2.33M) is above average for companies of similar size in the Australian market ($USD883.01K).

Compensation vs Earnings: Philippe's compensation has been consistent with company performance over the past year.

CEO

Philippe Wolgen (61 yo)

19.2yrs

Tenure

AU$3,742,412

Compensation

Dr. Philippe Jacques Wolgen, MBA, M.D., has been the Chief Executive Officer and Managing Director of Clinuvel Pharmaceuticals Limited since November 28, 2005 to lead the corporate turnaround of the Group....

Leadership Team

NamePositionTenureCompensationOwnership
Philippe Wolgen
CEO, MD & Director19.2yrsAU$3.74m6.86%
A$ 41.1m
Dennis Wright
Chief Scientific Officer12.3yrsAU$782.61k0.38%
A$ 2.3m
Peter Vaughan
Chief Financial Officerless than a yearno datano data
Lachlan Hay
Chief Operations Officerno datano datano data
Malcolm Bull
Head of Australian Operations & Investor Relationsno datano datano data
Rose Quadbeck-Diel
Senior Vice President of Regulatory Affairs1.1yrsno datano data
Azza Hamila
Head of Quality Assurance & Drug Safety1.1yrsno datano data
Claire Newstead-Sinclair
Company Secretaryless than a yearno datano data

1.1yrs

Average Tenure

Experienced Management: CUV's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Philippe Wolgen
CEO, MD & Director19.3yrsAU$3.74m6.86%
A$ 41.1m
Pearl Grimes
Non-Executive Directorless than a yearno datano data
Matthew Pringle
Non-Executive Directorless than a yearno datano data
Susan Smith
Non-Executive Director5.3yrsAU$80.00k0.00084%
A$ 5.0k
Jeffrey Rosenfeld
Non-Executive Chairman5.2yrsAU$91.67k0.0063%
A$ 37.7k
Karen Agersborg
Non-Executive Director7yrsAU$75.00k0.028%
A$ 165.9k
Guy van Dievoet
Non-Executive Directorless than a yearno datano data

5.2yrs

Average Tenure

Experienced Board: CUV's board of directors are considered experienced (5.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 04:53
End of Day Share Price 2025/01/02 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Clinuvel Pharmaceuticals Limited is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas WakimBell Potter
Norbert KalliwodaDr. Kalliwoda Research
David StantonJefferies LLC